• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Calcium channel blocker use not associated with increased risk of cancer

byDeepti Shroff KarhadeandDavid Wang
January 25, 2016
in Cardiology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a population-based study of over 800 000 patients, calcium channel blocker (CCB) use was not associated with an increased risk of cancer compared to patients with no CCB exposure or patients on other anti-hypertensive medications.

Evidence Rating Level: 3 (Average)

Study Rundown: CCBs are one of the most widely prescribed medications worldwide for the management of angina, hypertension, and other cardiovascular diseases. However, previous studies have suggested that CCB exposure may interfere with apoptosis resulting in a potential increased risk of cancer. Previous retrospective reviews have demonstrated conflicting results regarding the association between CCB use and cancer. The purpose of this large, population-based study was to investigate the relationship between CCB use and the incidence of cancer.

The study reviewed medication use and health record data from over 800 000 patients in 2 national patient databases in the United Kingdom (UK) and compared the incidence of cancer between patients exposed to CCBs, patients with no exposure to CCB (non-CCB), and patients not exposed to CCB, but with exposure to an alternative antihypertensive medication (AHT). At the conclusion of the trial, CCB treatment was not associated with an increased incidence of cancer compared to those treated with non-CCB or AHT. This association was consistent across multiple cancer types, including breast, colon, and prostate. The results of this study support the hypothesis that CCB exposure is not associated with increased risk of cancer. The study was strengthened by a large sample size and a long follow-up period. However, the patient database is only representative of the UK population, which limits the generalizability to ethnically diverse populations.

Click to read the study in BMJ Open

Relevant Reading: Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?

In-Depth [retrospective cohort]: This study reviewed medication use data and patient outcomes of all adults aged 18 to 79 from the Clinical Practice Research Datalink (CPRD) and the National Cancer Registration System (NCRS) for the study period of 1996 to 2009. Overall, 865 647 patients were included and divided into 3 groups based on medication exposure: 1) patients exposed to CCB (n =150 750), 2) no exposure to CCB (n = 557 931), and 3) exposure to AHT (n = 156 966). CCB and AHT exposures were defined as having at least 1 prescription during the study time period. The primary outcome was the incidence of primary cancer and carcinoma in situ of known origin. At the conclusion of the trial, there were no significant differences between the incidence of cancer in the CCB cohort compared to the non-CCB or AHT groups. The adjusted hazard ratio (HR) for all cancers for the CCB group compared to the non-CCB and AHT groups were 0.88 (95% CI: 0.86 to 0.89) and 1.01 (95% CI: 0.98 to 1.04), respectively. In subgroup analysis, no significant differences were seen in the incidence of breast, colon, and prostate cancers between the CCB and AHT group.

RELATED REPORTS

#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

The CREOLE trial: amlodipine and either hydrochlorothiazide or perindopril optimally lowers blood pressure in black African patients

Image: CC/wiki/MorgueFile

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: calcium channel blocker (CCB)
Previous Post

AAP addresses neonatal pain prevention

Next Post

Annual fecal immunochemical test screening associated with high sensitivity for colorectal cancer

RelatedReports

#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes
StudyGraphics

#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

December 2, 2021
Intrapartum serum prolactin may predict risk of postpartum diabetes
Cardiology

Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

November 23, 2021
UTI associated with increased risk of preeclampsia
Cardiology

The CREOLE trial: amlodipine and either hydrochlorothiazide or perindopril optimally lowers blood pressure in black African patients

June 23, 2019
Next Post
Development of a risk index for colorectal cancer screening

Annual fecal immunochemical test screening associated with high sensitivity for colorectal cancer

Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

Computed tomography improves diagnostic certainty in the emergency department

CT of the chest, abdomen, and pelvis demonstrates low diagnostic yield in low-velocity trauma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer
  • Several factors influence health programs conducted in the African American Church
  • Imiquimod noninferior to surgery in management of vulvar high-grade squamous intraepithelial lesions
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.